The aim of this review from NCBI was to describe the state of art about the pre-clinical research, the potential use and when existing, the clinical evidence related to CBD in the neurological field.
It is important to notice that in this research, 6 Italian
university departments took part
BACKGROUND:
Cannabidiol (CBD) is among the major secondary metabolites of Cannabis devoid of the delta-9-tetra-hydrocannabinol psychoactive effects. It is a resorcinol-based compound with a broad spectrum of potential therapeutic properties, including neuroprotective effects in numerous pathological conditions. CBD neuroprotection is due to its antioxidant and antiinflammatory activities and the modulation of a large number of brain biological targets (receptors, channels) involved in the development and maintenance of neurodegenerative diseases.